Global Multiple Myeloma (Kahler Disease) Therapeutics Pipeline Review 2016 - Drug Profiles of 143 Companies/Institutions - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016" report to their offering.

'Multiple Myeloma - Pipeline Review, H1 2016'; Multiple Myeloma (Kahler Disease) pipeline therapeutics constitutes close to 297 molecules. Out of which approximately 259 molecules are developed by Companies and remaining by the Universities

Institutes.

Multiple Myeloma (Kahler Disease) Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

The report 'Multiple Myeloma - Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 63, 62, 1, 2, 91, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 7, 18 and 7 molecules, respectively.

Companies Mentioned

  • 4SC AG
  • AB Science SA
  • AbbVie Inc.
  • Ablynx NV
  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.
  • Active Biotech AB
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech, Inc.
  • Affimed GmbH
  • AIMM Therapeutics B.V.
  • Altor BioScience Corporation
  • Amgen Inc.
  • Anthera Pharmaceuticals Inc.
  • APIM Therapeutics AS
  • APO-T B.V.
  • Arcarios BV
  • Arno Therapeutics, Inc.
  • Array BioPharma Inc.
  • Arvinas, Inc.
  • Asana BioSciences, LLC
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Atara Biotherapeutics, Inc.
  • Aurigene Discovery Technologies Limited
  • Bellicum Pharmaceuticals, Inc.
  • BioInvent International AB
  • Biotest AG
  • bluebird bio, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Celgene Corporation

For more information visit http://www.researchandmarkets.com/research/cnp93m/multiple_myeloma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Skin Cancer Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Skin Cancer Drugs